209 related articles for article (PubMed ID: 35426497)
1. PET/CT and PET/MRI in neuroendocrine neoplasms.
Rajamohan N; Khasawneh H; Singh A; Suman G; Johnson GB; Majumder S; Halfdanarson TR; Goenka AH
Abdom Radiol (NY); 2022 Dec; 47(12):4058-4072. PubMed ID: 35426497
[TBL] [Abstract][Full Text] [Related]
2. PET/MRI imaging in neuroendocrine neoplasm.
Virarkar MK; Montanarella M; Itani M; Calimano-Ramirez L; Gopireddy D; Bhosale P
Abdom Radiol (NY); 2023 Dec; 48(12):3585-3600. PubMed ID: 36525051
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
4. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
5. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
6. Role of Combined
Kaewput C; Vinjamuri S
Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204371
[TBL] [Abstract][Full Text] [Related]
7. Gastro-Entero-Pancreatic Tumors: FDG Positron Emission Tomography/Computed Tomography.
Khatri W; Spiro E; Henderson A; Rowe SP; Solnes LB
PET Clin; 2023 Apr; 18(2):243-250. PubMed ID: 36707371
[TBL] [Abstract][Full Text] [Related]
8. Clinical Usefulness of
Rinzivillo M; Partelli S; Prosperi D; Capurso G; Pizzichini P; Iannicelli E; Merola E; Muffatti F; Scopinaro F; Schillaci O; Salgarello M; Falconi M; Delle Fave G; Panzuto F
Oncologist; 2018 Feb; 23(2):186-192. PubMed ID: 29118267
[TBL] [Abstract][Full Text] [Related]
9. Role of positron emission tomography in thyroid and neuroendocrine tumors.
Treglia G; Kroiss AS; Piccardo A; Lococo F; Santhanam P; Imperiale A
Minerva Endocrinol; 2018 Sep; 43(3):341-355. PubMed ID: 28949122
[TBL] [Abstract][Full Text] [Related]
10. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
11. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
12. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.
Saleh M; Bhosale PR; Yano M; Itani M; Elsayes AK; Halperin D; Bergsland EK; Morani AC
Abdom Radiol (NY); 2022 Sep; 47(9):3078-3100. PubMed ID: 33095312
[TBL] [Abstract][Full Text] [Related]
13. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
[TBL] [Abstract][Full Text] [Related]
14. The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience.
Mohamed A; Asa SL; Lee Z; Tirumani SH; Li Q; Avril N; Bajor D; Mahipal A; Chakrabarti S; Selfridge JE; Kardan A
J Gastrointest Oncol; 2023 Apr; 14(2):1087-1094. PubMed ID: 37201086
[TBL] [Abstract][Full Text] [Related]
15. Added value of [
Yoo J; Kim SH; Jeon SK; Bae JS; Han JK
Eur Radiol; 2021 Oct; 31(10):7734-7745. PubMed ID: 33787974
[TBL] [Abstract][Full Text] [Related]
16. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
17. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
[TBL] [Abstract][Full Text] [Related]
18. Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI.
Arnfield EG; Tam L; Pattison DA; Younger J; Chikatamarla VA; Wyld D; Burge M; McCormack L; Ladwa R; Ramsay S
J Nucl Cardiol; 2023 Dec; 30(6):2676-2691. PubMed ID: 37587328
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and Treatment of Lung Neuroendocrine Neoplasms: Somatostatin Receptor PET Imaging and Peptide Receptor Radionuclide Therapy.
Park H; Subramaniam RM
PET Clin; 2023 Apr; 18(2):223-231. PubMed ID: 36585338
[TBL] [Abstract][Full Text] [Related]
20. Circulating hsa-miR-5096 predicts
Bocchini M; Tazzari M; Ravaioli S; Piccinini F; Foca F; Tebaldi M; Nicolini F; Grassi I; Severi S; Calogero RA; Arigoni M; Schrader J; Mazza M; Paganelli G
Front Oncol; 2023; 13():1136331. PubMed ID: 37287922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]